Leukemia Clinical Trials in Philadelphia

Showing 401-420 of 1,502 trials

huCART19-IL18 in CD19+ Cancers

NCT04684563

The purpose of this study is to evaluate the safety and feasibility of huCART19-IL18 cells in patients with relapsed or refractory CD19+ cancers.

Chronic Lymphocytic LeukemiaNon-hodgkin LymphomaAcute Lymphoblastic Leukemia

University of Pennsylvania72 participantsStarted May 2021

Philadelphia, Pennsylvania, United States

RECRUITINGNA< 1 mile

Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention - US Cohort Study

NCT05287451

This is a prospective preference study that will evaluate non-inferiority of the innovative treatment (RRS with delayed RRO) as compared to the standard treatment (RRSO) with respect to high grade serous (ovarian) cancer incidence

Ovarian CancerFallopian Tube Cancer

M.D. Anderson Cancer Center100 participantsStarted May 2022

Boston, Massachusetts, United States • Rochester, Minnesota, United States • St Louis, Missouri, United States +6 more locations

COMPLETEDPhase 2< 1 mile

Carboplatin and Paclitaxel With or Without Ramucirumab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Thymic Cancer That Cannot Be Removed by Surgery

NCT03694002

This randomized phase II trial studies how well carboplatin and paclitaxel with or without ramucirumab work in treating patients with thymic cancer that has spread to other places in the body, has come back, or cannot be removed by surgery. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as ramucirumab, may interfere with the ability of tumor cells to grow and spread. It is not yet known if giving carboplatin and paclitaxel with or without ramucirumab will work better in treating patients with thymic cancer.

Locally Advanced Thymic CarcinomaMetastatic Thymic CarcinomaRecurrent Thymic Carcinoma+1 more

SWOG Cancer Research Network21 participantsStarted Mar 2019

Anchorage, Alaska, United States • Anchorage, Alaska, United States • Anchorage, Alaska, United States +251 more locations

huCART19-IL18 in CD19+ Cancers

Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention - US Cohort Study

Carboplatin and Paclitaxel With or Without Ramucirumab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Thymic Cancer That Cannot Be Removed by Surgery

Leukemia Trials in Other Cities

Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.

A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS

The Myelin Disorders Biorepository Project

Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC).

Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer

Testing the Anti-cancer Drug Darolutamide in Patients With Testosterone-Driven Salivary Gland Cancers

Temozolomide With or Without Veliparib in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer

A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement

Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors (MK-2140-002)

Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors

A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer

Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab

A Study of XMT-1660 in Participants With Solid Tumors

Testing Oral Decitabine and Cedazuridine (ASTX727) in Combination With Venetoclax for Higher-Risk Acute Myeloid Leukemia Patients

Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia

Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung Cancer

Other Conditions in Philadelphia